Literature DB >> 31606735

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.

Andrea Giustina1, Ariel Barkan2, Albert Beckers3, Nienke Biermasz4, Beverly M K Biller5, Cesar Boguszewski6, Marek Bolanowski7, Vivien Bonert8, Marcello D Bronstein9, Felipe F Casanueva10, David Clemmons11, Annamaria Colao12, Diego Ferone13, Maria Fleseriu14, Stefano Frara1, Monica R Gadelha15, Ezio Ghigo16, Mark Gurnell17, Anthony P Heaney18, Ken Ho19, Adriana Ioachimescu20, Laurence Katznelson21, Fahrettin Kelestimur22, John Kopchick23, Michal Krsek24, Steven Lamberts25, Marco Losa26, Anton Luger27, Pietro Maffei28, Monica Marazuela29, Gherardo Mazziotti30, Moises Mercado31, Pietro Mortini26, Sebastian Neggers32, Alberto M Pereira4, Stephan Petersenn33, Manel Puig-Domingo34, Roberto Salvatori35, Ilan Shimon36, Christian Strasburger37, Stylianos Tsagarakis38, A J van der Lely32, John Wass39, Maria Chiara Zatelli40, Shlomo Melmed8.   

Abstract

OBJECTIVE: The aim of the Acromegaly Consensus Group was to revise and update the consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013. PARTICIPANTS: The Consensus Group, convened by 11 Steering Committee members, consisted of 45 experts in the medical and surgical management of acromegaly. The authors received no corporate funding or remuneration. EVIDENCE: This evidence-based consensus was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence following critical discussion of the current literature on the diagnosis and treatment of acromegaly comorbidities. CONSENSUS PROCESS: Acromegaly Consensus Group participants conducted comprehensive literature searches for English-language papers on selected topics, reviewed brief presentations on each topic, and discussed current practice and recommendations in breakout groups. Consensus recommendations were developed based on all presentations and discussions. Members of the Scientific Committee graded the quality of the supporting evidence and the consensus recommendations using the GRADE system.
CONCLUSIONS: Evidence-based approach consensus recommendations address important clinical issues regarding multidisciplinary management of acromegaly-related cardiovascular, endocrine, metabolic, and oncologic comorbidities, sleep apnea, and bone and joint disorders and their sequelae, as well as their effects on quality of life and mortality. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  acromegaly; comorbidities; consensus; diagnosis; treatment

Mesh:

Year:  2020        PMID: 31606735     DOI: 10.1210/clinem/dgz096

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Continuous Glucose Monitoring System in Acromegalic Patients: Possible Role in the Assessment of Glycemia Control.

Authors:  Valeria Mercuri; Tania D'Amico; Denise Costa; Corrado De Vito; Luca D'Angelo; Riccardo Schiaffini; Patrizia Gargiulo
Journal:  J Diabetes Sci Technol       Date:  2020-08-13

2.  Extraocular Muscle Enlargement in Growth Hormone-Secreting Pituitary Adenomas.

Authors:  B Coutu; D A Alvarez; A Ciurej; K Moneymaker; M White; C Zhang; A Drincic
Journal:  AJNR Am J Neuroradiol       Date:  2022-03-17       Impact factor: 3.825

Review 3.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

Review 4.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

5.  Pituitary adenoma…nomen omen?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2021-06-10       Impact factor: 3.633

Review 6.  Hyperprolactinemia and bone.

Authors:  Luigi di Filippo; Mauro Doga; Eugenia Resmini; Andrea Giustina
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

7.  Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.

Authors:  Pamela U Freda; Jeffrey N Bruce; Carlos Reyes-Vidal; Simran Singh; Yessica DeLeon; Zhezhen Jin; Alexander G Khandji; Serge Cremers; Kalmon D Post
Journal:  Pituitary       Date:  2020-10-30       Impact factor: 4.107

8.  COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.

Authors:  M Puig-Domingo; M Marazuela; B O Yildiz; A Giustina
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

Review 9.  The Interaction of Insulin and Pituitary Hormone Syndromes.

Authors:  Marie Helene Schernthaner-Reiter; Peter Wolf; Greisa Vila; Anton Luger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

10.  Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.

Authors:  Eva C Coopmans; Mark R Postma; Thalijn L C Wolters; Sebastiaan W F van Meyel; Romana Netea-Maier; André P van Beek; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.